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Abstract: The enzyme-coupled transient receptor potential channel subfamily M member 7, TRPM7,
has been associated with immunity and immune cell signalling. Here, we review the role of this
remarkable signalling protein in lymphocyte proliferation, differentiation, activation and survival.
We also discuss its role in mast cell, neutrophil and macrophage function and highlight the potential of
TRPM7 to regulate immune system homeostasis. Further, we shed light on how the cellular signalling
cascades involving TRPM7 channel and/or kinase activity culminate in pathologies as diverse as
allergic hypersensitivity, arterial thrombosis and graft versus host disease (GVHD), stressing the need
for TRPM7 specific pharmacological modulators.
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1. Introduction
The melastatin-like TRPM7 channel conducts divalent cations, specifically calcium (Ca2+),
magnesium (Mg2+) and zinc (Zn2+) [1–3]. It has been implicated in cellular and systemic Mg2+
homeostasis [4–6], Zn2+-mediated toxicity [7,8] and intracellular Ca2+ signalling [9–12]. The TRPM7
channel is considered to be constitutively active and its activity to be negatively regulated by
intracellular cations (Mg2+, Ba2+, Sr2+, Zn2+, Mn2+), Mg-ATP, polyamines, chloride (Cl−) and
bromide (Br−) concentrations, low intracellular pH and hydrolysis of the acidic phospholipid
phosphatidylinositol 4,5-bisphosphate (PIP2) [13–16]. Resting free cytosolic Mg2+ (0.5–1 mM [Mg2+]c)
and Mg-ATP (3–9 mM) concentrations [17] seem to be sufficient to block native TRPM7 channel
activity [4,18–20]. TRPM7’s unique enzyme encodes a serine-threonine kinase closely related to
eukaryotic elongation factor-2 kinase [21], phosphorylating mainly within α-helical loops [22]. A few
in vitro TRPM7 kinase substrates have been identified early on, including annexin A1 [23,24], myosin
II heavy chain [25] and PLCγ2 [26]. Only recently, with the development of novel mouse models,
the first native kinase substrate, SMAD2, was discovered, paving the way for more to follow [11,20,27].
Genetic disruption of TRPM7 in mice (Trpm7−/−) is embryonic lethal [4,28]. Deletion of
the exons encoding the TRPM7 kinase domain only (Trpm7∆k/∆k) also leads to early embryonic
lethality [4]. However, the latter phenotype could be attributed to a reduction in channel activity
in this mutant, particularly, as mice bearing a single point mutation at the active site of the
kinase (K1646R, Trpm7R/R), thus inactivating its catalytic activity, are viable and display no obvious
phenotype [29,30]. Heterozygous Trpm7+/∆k mice are also viable but develop hypomagnesaemia
upon Mg2+ restriction [4]. Deletion of the TRPM7 kinase domain at amino acid (aa) 1538 yields in
reduced current amplitudes, while caspase-induced deletion at aa 1510 results in enhanced TRPM7
currents [4,31]. Inactivation of kinase activity via the K1646R mutation (Trpm7R/R), though, does not
affect current development [29,30,32] (Figure 1). However, it was reported to show increased
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basal current activity right after break-in in macrophages [29]. Recently, it was shown that the
Mg2+-sensitivity of the TRPM7 channel is reduced almost two-fold in kinase-deficient Trpm7R/R mouse
mast cells. The tested Mg2+ concentrations, however, suggest that this effect will not influence TRPM7
currents in intact cells with [Mg2+]c close to 1 mM [20]. Accordingly, how TRPM7 channel and kinase
activities affect each other is still incompletely understood. It is thought that they are interdependent in
that Mg2+ enters through the channel pore and the kinase domain requires Mg2+ ions to function [3,22],
while the kinase domain rather than the catalytic activity are crucial for channel function [4,29–31].
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Figure 1. TRPM7 topology. Each TRPM7 protein consists of six transmembrane segments (1 to 6) 
with the channel pore located between segment 5 and 6. Within the N-terminus are melastatin 
homology domains (MHD), characteristic for TRPM family members. The cytoplasmic C-terminus 
contains a transient receptor potential domain (TRP), a coiled-coil domain (CC) and a kinase 
substrate domain (SD) upstream the atypical α-type serine/threonine protein kinase domain (KD). 
Mutation at the catalytic side of the kinase (K1646R) abolishes kinase activity without affecting 
current activity. Deletion of the KD at different amino acids (aa) results in either enhanced or 
reduced current activity. The black star indicates the location of the point mutation, crosses mark the 
kinase deletion. TRPM7 is negatively regulated by depletion of phosphatidylinositol 
4,5-bisphosphate (PIP2), physiologic free cytosolic magnesium concentrations [Mg2+]c, Mg-ATP, 
polyamines, low pH and chloride (Cl−) and bromide (Br−) concentrations. 
TRPM7 kinase requires Mn2+ or Mg2+ for its activity and uses mainly Mg-ATP for 
phosphorylation [22]. Massive auto-phosphorylation of TRPM7 increases kinase activity and 
substrate recognition [33–36]. Considering the ubiquitous expression of TRPM7, it is not surprising 
that the protein has a fundamental and non-redundant role in cellular physiology [1,37]. It is 
involved in processes as diverse as proliferation, growth, migration, apoptosis, differentiation and 
exocytosis [38]. Tissue-specific deletion of TRPM7 in thymocytes or macrophages, as well as 
inactivation of the kinase activity (Trpm7R/R) in mice, highlight the importance of this unique 
signalling protein for an operating immune system that is still kept in check [20,28,39]. 
  
Figure 1. TRPM7 topology. Each TRPM7 protein co sist of six transmembra ents (1 to 6) with the
channel pore located between segment 5 and 6. Within the N-terminus are melastatin homology domains
(MHD), characteristic for TRPM family members. The cytoplasmic C-terminus contains a transient receptor
potential domain (TRP), a coiled-coil domain (CC) and a kinase substrate domain (SD) upstream the
atypical α-type serine/threonine protein kinase domain (KD). Mutation t the catalytic side of the kinase
(K1646R) abolishes kinase activity without affecting current activity. Deletion of the KD at different amino
acids (aa) results in either enhanced or reduced current activity. The black star indicates the location
of the point mutation, crosses mark the kinase deletion. TRPM7 is negatively regulated by depletion
of phosphatidyli ositol 4,5-bisp sphate (PIP2), physiologic free cytosolic magnesium concentrations
[Mg2+]c, Mg-ATP, polyamines, low pH and chloride (Cl−) and bromide (Br−) concentrations.
TRPM7 kinase requires Mn2+ or Mg2+ for its activity and uses mainly Mg-ATP for phosphorylation [22].
Massive auto-phosphorylation of TRPM7 increas s kinase activity and substrate recognition [33–36].
Considering the ubiquitous expression of TRPM7, it is not surprising that the protein has a fundamental
and non-redundant role in cellular physiology [1,37]. It is involved in processes as diverse as
proliferation, growth, migration, apoptosis, differ ntiation and exocytosis [38]. Tissue-specific deletion
of TRPM7 in thymocytes or macrophages, as well as inactivation of the kinase activity (Trpm7R/R) in
mice, highlight the importance of this unique signalling protein for an operating immune system that
is still kept in check [20,28,39].
2. The Channel-Kinase TRPM7 in Immune Cell Signalling
2.1. TRPM7 Kinase Regulates Mast Cell Reactivity
Mast cells are associated with the progression of different pathologies such as immediate and
delayed hypersensitivity reactions, arthritis, atherosclerosis, heart failure, as well as neuroinflammatory
diseases [40–42]. Upon stimulation, mast cells release granules, filled with inflammatory mediators
such as histamine, proteases, cytokines and growth factors [43,44]. Mast cells are present in all
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organs in close proximity to blood vessels, neurons and lymphatic vessels, thus disseminating local
inflammatory signals [40]. While classically, mast cells are activated via crosslinking of the IgE
receptor (FcεRI) upon antigen binding [45], their activation can be triggered by many other stimuli
including toll-like receptor (TLR) ligands, complement and neuropeptides. Receptor stimulation in
mast cells leads to a network of stimulatory and inhibitory signals [44] encoded via intricate Ca2+
signalling events [46,47]. Store operated Ca2+ entry is essential for mast cell activation in vitro and
in vivo [48,49]. Recently, TRPM7 has been implicated in receptor-induced Ca2+ release as well as
store-operated Ca2+ entry [9,12]. In primary human lung mast cells (HLMCs) and in the human
mast cell lines, LAD2 and HMC-1, TRPM7 expression and function was shown to be essential
for cell survival. Using adenoviral-mediated knock-down of TRPM7 in HLMC or HMC-1 authors
observed enhanced cell death, which was not rescued by extracellular Mg2+ supplementation [50].
First indications that TRPM7 is involved in degranulation processes and release of cytokines in rat
bone marrow-derived mast cells (BMMCs) were gained in 2014. TRPM7 mRNA expression levels
were significantly higher in asthmatic rat BMMCs than in controls. Genetic or pharmacological
inhibition of TRPM7 significantly decreased β-hexosaminidase activity and secretion of histamine as
well as the release of the pro-inflammatory cytokines IL-6, IL-13 and TNF-α in the asthmatic group
compared to the control group. Authors concluded that inhibition of TRPM7 currents reduces mast
cell degranulation and cytokine release [51]. However, functional TRPM7 channel or kinase activities
were not shown. The pharmacological antagonist used to inhibit TRPM7, 2-Aminoethoxydiphenyl
Borate (2-APB), supposedly only blocks channel and not kinase activity but has various off-target
effects. Importantly, at the applied concentrations (100–200 µM) 2-APB blocks store operated Ca2+
entry (SOCE) via inhibition of Ca2+ release activated calcium (CRAC) channels [52]. Thus, it is possible
that observed 2-APB effects were in fact not mediated by TRPM7 but SOCE. Authors, however,
confirm the reduction in β-hexaminidase activity as well as in histamine and cytokine release, using a
lentiviral siRNA-mediated knock-down of TRPM7 in primary BMMCs [51]. Nonetheless, the question
remained, whether kinase and/or channel activity were responsible for the observed phenotype.
As kinase-deficient Trpm7R/R mutant mouse mast cells showed normal current amplitudes but no
kinase activity, this model allowed the independent study of TRPM7 channel versus kinase moieties in
mast cells [32]. Utilizing the two TRPM7 kinase mutant mouse models (Trpm7+/∆k, Trpm7R/R), it was
shown that the kinase regulated G protein-coupled receptor-activated histamine release, independently
of channel activity. TRPM7 kinase activity, moreover, regulated Ca2+-sensitivity of G protein-triggered
mast cell degranulation. TRPM7 kinase-deficiency resulted in suppressed IgE-dependent exocytosis
and slower cellular degranulation rates. Besides, extracellular Mg2+ was necessary to guarantee
regulated IgE-induced exocytosis. Authors concluded that the TRPM7 kinase activity controls murine
mast cell degranulation and histamine release independently of TRPM7 channel function [32]. Thus,
TRPM7 might inflict its immune-modulatory role on mast cells via its kinase domain.
2.2. TRPM7 in Neutrophil Migration
Neutrophils, the most abundant leukocytes in the blood, are one of the key players of the innate
immune system, contributing to the clearance of acute inflammation and bacterial infection [53].
During acute inflammation neutrophils are one of the first responding cells. The signalling cascades
triggered after neutrophil activation start with migration of neutrophils towards the inflammatory
site. The cascade ends with elimination of pathogens via secretion of chemokines, which attract
other leukocytes, phagocytosis to maintain tissue homeostasis and degranulation and release of
neutrophil extracellular traps (NETs) to prevent the spread of the infection. It is well established
that Ca2+ signalling is pivotal for the recruitment cascade and activation of neutrophils, highlighting
the importance of ion channels for neutrophil function [54,55]. TRPM7 channel activity has been
implicated as a regulator of cell migration by facilitating Ca2+ oscillations [56–58]. Using a human
neutrophil cell line, it was shown that TRPM7 is recruited into lipid rafts in a CD147-dependent manner.
Knock-down of CD147, a glycoprotein required for neutrophil recruitment and chemotaxis, caused
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significant decrease in lipid raft localization of TRPM7. Thus, TRPM7 was suggested to be involved in
the CD147-triggered Ca2+-induced chemotaxis, adhesion and invasiveness of human neutrophils [59].
However, Wang and colleagues did not show functional TRPM7 ion channel activity and one needs to
keep in mind that neutrophil-like cell lines are controversially discussed regarding their comparability
to primary neutrophils [53]. During acute lung injury (ALI), the permeability of the alveolar-capillary
membrane is increased, which in turn can lead to migration of neutrophils [60]. A septic rat model
treated with salvianolic B showed that sepsis-induced ALI was reduced due to decreased levels of
TRMP6 and TRPM7 mRNA in lung tissue, potentially linking TRPM7 to neutrophil migration and
infiltration [61]. As patients with inherited neutrophil deficiencies suffer from severe infections that
are often fatal, underscoring the importance of this cell type in immune defence, it is critical to gain
a better understanding of the role of TRPM7 channel and kinase activities in the signalling cascades
triggering neutrophil migration [53].
2.3. TRPM7 Guides Macrophage Activation and Polarization
Blood monocytes and tissue macrophages are major components of innate immunity, strategically
positioned throughout the body tissues to orchestrate inflammatory processes. Similar to neutrophils,
they maintain tissue homeostasis via phagocytosis of dead cells, debris or potentially harmful
pathogens. As antigen presenting cells they are able to activate and coordinate the adaptive immune
system [62,63]. Various TRP proteins have been associated with macrophage-mediated inflammatory
responses [64]. TRPM7 has also been linked to the activation and proliferation of monocytes and
macrophages [29,65–68]. However, controversies on the role of TRPM7 for macrophage activation
in response to LPS remain [39,68]. On the one hand, TRPM7 channel activity was suggested to
be essential for macrophage proliferation and polarization into the alternate or anti-inflammatory
M2-subtype [68]. LPS and co-stimulatory cytokines IFN-γ (pro-inflammatory M1-type) or IL-4 and
IL-13 (anti-inflammatory M2-type) trigger the polarization of macrophages [69,70]. Interestingly,
the activity of TRPM7 increased significantly in response to stimulation with IL-4. The TRPM7 inhibitor
NS8593 [71] blocked IL-4 and M-CSF induced proliferation and reduced the inhibitory effect of IL-4 or
M-CSF on the LPS-induced expression of the pro-inflammatory cytokine TNF-α, thus, counteracting
the differentiation into the M2 subtype [68]. On the other hand, more recently, TRPM7 channel activity
has been implicated in macrophage activation in response to LPS and LPS-induced peritonitis [39].
In TRPM7-deficient macrophages (Trpm7fl/fl(LysM Cre)) IL-1β secretion was significantly reduced and
also the gene expression upon LPS stimulation was altered, indicating a key function of TRPM7 in the
activation process of macrophages. In addition, it was found that TRPM7 is pivotal for the endocytosis
of LPS-TLR4-CD14 signalling complexes with TRPM7-deficient macrophages showing significantly
reduced internalization of TLR4 and CD14. Schappe et al. demonstrated that these defects upon
LPS stimulation were due to diminished TRPM7-mediated Ca2+ influx. They speculate that TRPM7
not only controls TLR4 internalization but also regulates downstream IRF3 and NFκB signalling by
mediating cytosolic Ca2+ elevations. Moreover, in a LPS-dependent model of peritonitis, Trpm7fl/fl
(LysM Cre) mice had decreased serum cytokine levels after LPS treatment, preventing pathological
inflammation. Specifically, the expression levels of Tnfa and Il1b were significantly reduced, resulting
in a diminished recruitment of immune cells into the peritoneum. Thus, Trpm7fl/fl (LysM Cre) mice
were protected from the development of LPS-induced peritonitis. Consequently, it was suggested that
TRPM7 channel blockade could be beneficial for the treatment of chronic infections or septic shock [39].
The difference in the macrophage response to LPS might depend on different protocols used. However,
to date there is no consensus, whether LPS induces Ca2+ elevations resulting in macrophage activation.
Several studies have found no changes in cytosolic Ca2+ concentrations in response to LPS treatment
in macrophages [72,73].
The role of TRPM7 kinase activity in macrophage or dendritic cell function is far less understood.
TRPM7 kinase-deficient mice (Trpm7R/R) show no defects in percentages of macrophages [29]. Also,
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Trpm7R/R CD11c+ dendritic cells develop normally and display regular major histocompatibility
complex II (MHCII) and integrin expression [20].
2.4. TRPM7 Affects Lymphocyte Functions
Lymphocytes forming the adaptive or acquired immune response are activated and regulated
by cells of the innate immune system, that is, macrophages and provide immunologic memory [74].
Antigen specific lymphocytes respond to pathogens with activation induced proliferation and clonal
expansion. This temporal proliferative burst is terminated with a return to cell quiescence and eventual
cell death. The autonomous timing of proliferation ensures an appropriate response magnitude whilst
preventing uncontrolled expansion. Thus, a detailed understanding of the regulatory principles
governing lymphocyte activation, proliferation, differentiation and survival is essential to a cohesive
picture of the immune system homeostasis [75].
2.4.1. TRPM7 Kinase Regulates Intracellular Calcium Signals and Proliferation in Lymphocytes
Upon T cell receptor (TCR) or B cell receptor (BCR) stimulation, phospholipase C (PLC) is
activated, catalysing the hydrolysis of PIP2 into diacylglycerol (DAG) and inositol (1,4,5) triphosphate
(IP3). Subsequently, IP3 triggers Ca2+-release from the endoplasmatic reticulum (ER) Ca2+-store via
the IP3-receptor (IP3R). Upon depletion of Ca2+ from the ER lumen, the stromal interaction molecule
(STIM) translocates to the plasma membrane and triggers SOCE via CRAC channels. This prolonged
increase in intracellular Ca2+ concentrations is essential for the nuclear factor of activated T cells
(NFAT) to translocate into the nucleus and induce transcription of genes essential for cell proliferation
and clonal expansion (Figure 2) [38].
Recently, Romagnani et al. revealed that TRPM7 kinase-dead (Trpm7R/R) CD4+ T cells show
slightly but significantly decreased Ca2+ signals upon stimulation with plate-bound anti-CD3/CD28
antibodies, whereas basal cytosolic Ca2+ concentrations ([Ca2+]c) were unaltered [20]. These experiments
were performed using extracellular 2 mM Ca2+ concentrations. Similarly, Beesetty et al. showed that
receptor-mediated Ca2+ signalling was significantly diminished in Trpm7R/R T cells using anti-CD3
crosslinking in 0.4 mM extracellular Ca2+ levels, and differences in 2 mM Ca2+ concentrations were
even more pronounced. Nevertheless, basal [Ca2+]c was also unchanged. In addition, SOCE was
decreased in Trpm7R/R splenocytes upon pre-treatment with phorbol 12-myristate 13-acetate (PMA)
and ionomycin, while there was no difference in ER-store Ca2+ content. Basal [Ca2+]c, however,
were lower in PMA and ionomycin pre-activated Trpm7R/R T cells compared to wild-type (WT) [10].
These results are in line with recent studies, suggesting that TRPM7 regulates store-operated Ca2+ entry.
Faouzi et al. linked TRPM7 channel and kinase moieties to direct involvement in SOCE. Trpm7-deficient
chicken B lymphocytes exhibited down-regulation of SOCE, which was mainly attributed to missing
kinase activity [12]. Moreover, it was shown that TRPM7 channels seem to be essential to sustain the
Ca2+ content of intracellular stores in resting cells. Authors speculate that TRPM7 kinase may directly
phosphorylate STIM2, thereby influencing Ca2+ entry via SOCE, yet found no effect on phosphorylation
of STIM1 or STIM2 [12].The first indication that TRPM7 activity is involved in SOCE was found in 2005.
Matsushita and colleagues reported that SOCE, in response to thapsigargin-induced store depletion,
was increased in HEK293 cells transfected with WT TRPM7 but did not change in cells transfected
with a kinase domain-deleted TRPM7∆KD (aa 1-1599) mutant construct, compared to mock transfected
controls. However, the described TRPM7∆KD mutant displayed almost no current activity, leaving
the question of the role of TRPM7 channel versus kinase moieties unanswered [76]. Also, the impact
of TRPM7 kinase activity on T cell proliferation efficiency, following Ca2+ signalling events, remains
controversial. While Romagnani et al. discovered that Trpm7R/R T cells proliferate independently of
their kinase activity in response to TCR stimulation (plate-bound anti-CD3/CD28) [20], Beesetty et al.
showed a reduced T cell proliferation, in response to PMA and ionomycin treatment during the
first 24 hours, which was compensated for after 48 and 72 hours [10]. As the reported reduction in
Ca2+ signalling was very small, using plate-bound anti-CD3/CD28 antibodies, it is not surprising
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that Trpm7R/R T cell proliferation was not altered [20]. The decrease in SOCE upon pre-treatment
with PMA ionomycin in Trpm7R/R splenocytes however, was much more pronounced, resulting in
reduced proliferation [10]. The combination of PMA—directly activating protein kinase C—with the
calcium ionophore ionomycin, which increases [Ca2+]c, is a fast and powerful stimulus, circumventing
classical receptor activation. Thus the observed alterations in proliferation depend on the experimental
conditions used, suggesting that TRPM7 kinase might influence proliferation depending on the stimuli
and that receptor-operated mechanisms might be compensating [10,20]. Summarizing, these studies
highlight a potential role of TRPM7 kinase activity in regulating Ca2+ signalling and subsequent
activation processes in T cells and suggest TRPM as key regulator of the temporal proliferative burst.
However, how exactly TRPM7 channel and kinase activities interplay to regulate Ca2+ signalling and
subsequent proliferation in T lymphocytes still needs further investigation.
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Figure 2. Role of TRPM7 kinase in calcium signalling and proliferation of T cells. Upon T cell
receptor (TCR) binding, phospholipase C (PLC) is activated and hydrolyses phosphatidylinositol
4,5-biphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). DAG in
conjunction with Ca2+ activates protein kinase C (PKC), thus inducing cell proliferation. IP3 induces
Ca2+ release from the endoplasmic reticulum (ER) via IP3 receptor (IP3R), followed by the translocation
of the stromal interaction molecule (STIM) to the plasma membrane. STIM triggers Ca2+ influx from
the extracellular space via ORAI/CRACM channels. Ca2+ is rapidly removed from the cytosol by the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), refilling the ER Ca2+ stores. The prolonged
increase in cytosolic Ca2+ concentrations leads to the activation of calcineurin, resulting in the
dephosphorylation and nuclear translocation of nuclear factor of activated T cells (NFAT) and
subsequent cytokine expression, e.g., interleukin 2 (IL-2), triggering clonal expansion of T cells.
2.4.2. TRPM7 in Cell Growth, Activation and Development of B Cells
A Trpm7-deficient B-lymphocyte cell line (chicken DT40 cells) exhibits a selective defect to
proliferate in regular media but can do so in media supplemented with 10 mM Mg2+. After 24 h
in regular media, TRPM7-deficient B cells accumulated in the G0/G1 phase of the cell cycle and were
reduced in average cell size. Authors conclude that TRPM7-deficient cells display a defect in growth,
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failing to increase in size and mass. This defect was attributed to the lack of signalling downstream of
phosphoinositide 3-kinase (PI3-K) with impaired mammalian target of rapamycin complex 1 (mTORC1)
signalling, ribosomal S6 kinase (S6K) and Akt activation, whereas ERK phosphorylation was unaltered.
Interestingly, overexpression of constitutively active AKT was not sufficient to overcome this growth
defect. However, provision of a heterologous sustained PI3K signal, utilizing a constitutively active
form of the catalytic subunit of PI3K, p110α, counteracted the failure of TRPM7-deficient cells to
grow and proliferate in regular media. Thus TRPM7 was positioned alongside PI3K signalling as
a central regulator of lymphocyte growth [77]. Moreover, TRPM7 was shown to be essential for
cell-cycle progression, as Trpm7-deficient DT40 B cells showed an up-regulation of p27kip, a key cell
cycle regulator which blocks the transition from G0 to S phase. The quiescence was reversible and
rescued by Mg2+ supplementation or TRPM7 overexpression [78]. Utilizing the same Trpm7-deficient
DT40 B cell line and a DT40 cell line expressing the kinase-dead mutant (K1648R), it was recently
shown that TRPM7 is essential for early events of B cell activation through both kinase and channel
activities. TRPM7 channel activity controlled antigen uptake and presentation to T cells [27]. Previously,
TRPM7 kinase has been suggested to regulate non-muscle myosin IIA filament stability as well as
actomyosin contractility by phosphorylating myosin IIA heavy chain [25], while the Mg2+ influx through
the channel was also correlated with maintenance of myosin II-dependent cytoskeletal organization [79].
TIRF microscopy revealed that expression of TRPM7 in B cells controlled actin dynamics and slowed
antigen internalization, resulting in prolonged B cell signalling. Authors conclude that TRPM7 signalling
is essential for B cell affinity maturation and antibody production [27]. Moreover, recent findings
indicate that TRPM7 expression is required for murine B cell development. Mice with tissue specific
deletion of TRPM7 in B cells failed to generate peripheral B cells due to a developmental defect
at the pro-B cell stage and increased apoptosis of B cell precursors in the bone marrow. In vitro
the development of Trpm7-deficient B cells could be rescued via Mg2+-supplementation. Whereas,
TRPM7 kinase-deficiency did not affect the development of B cells in the bone marrow or the percentage
of peripheral B cells. Interestingly, the deletion of the entire TRPM7 protein in B cells lead to increased
percentages of neutrophils, eosinophils and monocytes in the spleen of mutant mice, compared to WT
which could be attributed to the primary lack of B cells [80]. Thus, TRPM7 channel and kinase activities
seem unique and non-redundant for proper B cell function.
2.4.3. TRPM7 in Murine T Cell Development, Differentiation and Transcriptional Regulation
In murine T lymphocytes TRPM7 is required for thymic development and thymopoiesis.
Conditional knock-out of Trpm7 in the T cell lineage was shown to disrupt thymopoiesis,
with thymocytes remaining in the double negative (CD4−CD8−) state and resulted in altered
chemokine and cytokine expression profiles [28], indicating that TRPM7 channel and/or kinase
are important for T cell function. Using the homozygous kinase-dead Trpm7R/R mouse model,
recently it was shown that TRPM7 kinase activity is not essential for thymopoiesis [10,20]. However,
the enzymatic activity of TRPM7 is required for intra-epithelial T cell homeostasis. Trpm7R/R mice
almost completely lack gut intraepithelial T lymphocytes (IELs) [20]. Intestinal IELs represent a first
line of defence within the largest immune organ of our body [81]. Numerous effector T lymphocytes
differentiate in the intestine, from where they migrate into the periphery [82,83]. Thus, understanding
the gut immune system, harbouring ∼70% of the total lymphocytes in the human body, is of utmost
importance [81,84] for regulating of immune homeostasis. Analysis of the percentage of remaining
TRPM7R/R IELs revealed a significant reduction in pro-inflammatory TH17 cell subsets, while the
percentage of anti-inflammatory Treg cells was unaffected compared to WT. Consistently, the in vitro
differentiation of naïve Trpm7R/R T cells into TH17 cells was also compromised, while the Treg cell
differentiation proceeded unperturbed. These findings were coherent with the robust reduction of
IL-17 concentration in serum from Trpm7R/R mice [20]. As TGF-β/SMAD pathways are crucial for the
polarization of CD4+ T cells into TH17 cells [85], it is likely that the TGF-β/SMAD signalling pathway
is affected by TRPM7 kinase activity (Figure 3). Notably, Western Blot analysis of Trpm7R/R naïve CD4+
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T cells treated with TGF-β1 revealed a significant reduction in SMAD2 phosphorylation, while SMAD3
phosphorylation was unaltered. Analysis of the TGF-β1-induced SMAD2 translocation was also
significantly reduced in Trpm7R/R naïve CD4+ T cells. Thus, authors conclude that the TRPM7 kinase
regulates TH17 cell differentiation via TGF-β/SMAD2 dependent pathways. An in vitro kinase assay
using highly purified recombinant TRPM7 kinase, SMAD2, as well as C-terminally truncated SMAD2
revealed that TRPM7 phosphorylates SMAD2 in a dose dependent manner but fails to phosphorylate
the truncated SMAD2. Thus, the C-terminal Ser465/467-motif of SMAD2 was identified as a novel
substrate for the TRPM7 kinase [20]. The upregulation of the integrin αE, also known as CD103,
enables T cells to migrate into the gut epithelium [86,87] and is dependent on SMAD2 TGF-β/SMAD2
signalling cascades [88], which was significantly impaired in TGF-β-treated Trpm7R/R T cells. Using a
chromatin immunoprecipitation (ChIP) assay, the authors demonstrated a defective binding of SMAD2
to the Itgae (CD103) promoter in Trpm7R/R T cells in response to TGF-β. Consequently, the expression
of the gene encoding for CD103, Itgae, was also significantly reduced in primary Trpm7R/R IELs as
well as in response to TGF-β and T cell receptor co-stimulation in naïve Trpm7R/R T cells. Consistently,
the expression of the signature transcription factor for TH17 cells, Rorc, as well as the cytokine IL-17,
which both depend on SMAD2 phosphorylation and translocation into the nucleus, were also impaired
in Trpm7R/R T cells (Figure 3). Interestingly, the CD103 expression in Trpm7R/R CD11c+ dendritic cells
was normal, compared to WT [20]. If or how TRPM7 kinase is triggered via TGF-β stimulation in T cells
is still under investigation. One emerging concept, however, could involve a constitutively active
TRPM7 kinase that phosphorylates SMAD2 once it is anchored to the plasma membrane following
TGF-β receptor activation (Figure 3). Importantly, this selective defect of SMAD2 signalling in T cells
culminating in reduced pro-inflammatory TH17 cell differentiation, while leaving anti-inflammatory
Treg cell differentiation unaffected (Figure 4A,B), highlights the essential function of TRPM7 kinase in
immune homeostasis [20]. These results suggest that TRPM7 kinase might serve as molecular switch
from pro-inflammatory to anti-inflammatory milieu and highlights the potential of TRPM7 kinase
inhibition for the treatment of pro-inflammatory diseases.
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growth factor β1 (TGF-β1), the TGF-β receptor complex (TGFβRI/II) initiates the phosphorylation of Figure 3. TRPM7 kinase in T cell signalling and transcriptional regulation. U on binding of tumour
growth factor β1 (TGF-β1), the TGF-β receptor complex (TGFβRI/II) initiates the phosphorylation
of the c-terminal SXS-motif of SMAD2. Results gained from TRPM7 kinase deficient murine T cells
suggest an additional mechanism by which the TRPM7 kinase phosphorylates SMAD2 directly, once it
is anchored to the plasma membrane. Phosphorylated SMAD2 interacts with SMAD4 and promotes
the transcription of Itgae, Il-17 and Rorc genes. The interleukin 6 (IL-6) dependent STAT3 as well as
Erk1/2 phosphorylation pathway is unaltered in TRPM7 kinase deficient murine T cells.
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To date, very little is known regarding the role of TRPM7 in human lymphocytes. Pharmacological
inhibition of TRPM7 in a human T cell line results in growth arrest and reduced proliferation [89].
TRPM7 was suggested to be involved in the migration of activated human T cells, where it is located
in the uropod, in conjunction with the calcium-activated potassium channel, KCa3.1, facilitating T cell
migration. Knock-down via siRNA resulted in a significant reduction in number and velocity of
migrating cells [90]. Moreover, TRPM7 was associated with TNF-α-induced necroptosis in T cells.
Knock-down of TRPM7 in a T cell line protected it from necroptosis [91]. Nonetheless, it will be
necessary to determine if the observed crucial functions of TRPM7 kinase and channel moieties in
murine lymphocytes also applies to human counterparts.
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Figure 4. TRPM7 kinase is essential for T cell differentiation into the pro-inflammatory TH17
cell type and th dev lopment of g aft ver us host disease. (A) Naïve CD4+ T c lls differentiate
into ro-infla matory TH17 cells in the pres nce of TGF-β and IL-6. For the differentiation into
anti-i flammatory egulatory T cells (Tregs), t e cytokines TGF-β and IL-2 are required. (B) Genetic
inactivation of TRPM7 kinase activity (Trpm7R/R) results in reduced TH17 cell differentiation, indicated
via diminished Rorc and Il-17 mRNA expression as well as IL-17 serum levels, while Treg cell
differentiation, evident via FoxP3 expression and IL-10 serum levels, is unaltered. In addition,
integrin αE (CD103) expression is reduced in TRPM7 kinase deficient T cells. (C) Transplantation
of bone marrow cells (BMC, C57BL/6) in conjunction with splenocytes (SPL, C57BL/6) triggers the
development of graft versus host disease (GVHD) in lethally irradiated mice with different genetic
background (BALB/c), manifesting in massive tissue destruction of the intestine but also lung and skin
tissues. TRPM7 ki ase deficient BMC a d SPL transplantation does not induce inflammation in the
intestine and ameliorates or ev n prev s disease progression, suggesting TRPM7 kinase inhibition as
valid tool for the treatment of GVHD. n.a. (not altered).
3. TRPM7-Mediated Hematologic and Inflammatory Diseases
3.1. Hypomagnesaemia and TRPM7 Kinase in Delayed-Type Hypersensitivity Reactions
Mg2+ is a vital mineral macronutrient. Considering that low serum Mg2+ levels have also been
linked to memory decline, neurodegenerative diseases, decrease in muscle performance, heart failure,
certain cancers, autoimmune diseases and allergic reactions, it is of critical importance to further
identify the mechanisms regulating the availability of this macronutrient [92,93]. Recently, it was
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shown that TRPM7, in conjunction with its sister channel TRPM6, regulates systemic Mg2+ homeostasis
via absorption of Mg2+ in the intestine [94]. The interconnection between nutrient metabolism and the
immune system occurs at many levels, ranging from endocrine signalling to direct sensing of nutrients
by immune cells [95]. Interestingly, adult Trpm6-deficient mice suffered from hypomagnesaemia and
displayed a degeneration of many lymphoid organs. The thymus of mutant mice was only rudimentary
present with an essentially undistinguishable cortex region. Also, the red pulp of the spleens
of Trpm6-deficient mice was substantially reduced. Dietary Mg2+ supplementation rescued these
phenotypes, indicating that indeed hypomagnesaemia was responsible for the observed deficits [94].
While homozygous genetic deletion of the ubiquitously expressed TRPM7 kinase domain in
mice leads to early embryonic lethality, heterozygous Trpm7+/∆k mice are viable and develop a severe
hypomagnesaemia upon Mg2+ restriction, leading to increased mortality, susceptibility to seizures as
well as prevalence for allergic hypersensitivity [4]. It is known that low, systemic Mg2+ levels correlate
with cell-extrinsic enhancement of systemic inflammatory and allergic responses [96]. To evaluate the
level of delayed-type hypersensitivity responses in Trpm7+/∆k mice, oxazolone sensitization experiments
were performed. Trpm7+/∆k mice displayed an elevated oxazolone-induced contact hypersensitivity,
compared to WT [4]. Interestingly, homozygous mice with genetic inactivation of TRPM7 kinase
activity, via a point mutation within the active site of the kinase, Trpm7R/R, were viable and did
not develop hypomagnesaemia or hypersensitivity responses. In fact, they even displayed reduced
oxazolone-induced delayed type hypersensitivity responses [30]. Their systemic Mg2+ and Ca2+
levels were similar to WT, as the channel function was not affected by the point mutation [29,30,32].
Since allergic reactions are triggered by mast cell-mediated histamine release, the role of TRPM7 in mast
cell degranulation and histamine release was studied using Trpm7+/+, Trpm7+/∆k and Trpm7R/R mice.
As reported, degranulation and histamine release proceeded independently of TRPM7 channel function.
However, as extracellular Mg2+ was essential to control unperturbed IgE-DNP-dependent exocytosis
and removal of Mg2+ exaggerated histamine release, the observed differences in hypersensitivity
responses could be attributed to the different systemic Mg2+ levels in Trpm7+/∆k versus Trpm7R/R
mice. G-protein-coupled receptor stimulation revealed strong suppression of histamine release in
both kinase-deficient mast cells (Trpm7+/∆k and Trpm7R/R), whereas removal of extracellular Mg2+
caused the phenotype to revert, suggesting that the TRPM7 kinase activity regulates murine mast cell
degranulation by changing its sensitivity to intracellular Ca2+ and extracellular Mg2+ concentrations [32].
Thus, TRPM7 might inflict its immune-modulatory role by sensing cations via its kinase domain. To date,
little is known about activation mechanisms or physiologic substrates of TRPM7 kinase.
3.2. The TRPM7 Channel-Kinase in Arterial Thrombosis and Stroke
TRPM7 kinase has been suggested to regulate myosin IIB filament stability as well as actomyosin
contractility by phosphorylating myosin IIA [25]. Recently, it was shown that TRPM7 channel activity
also affects myosin IIA activity independently of kinase function. In conditional Trpm7-deficient
mice (Trpm7fl/fl-Pf4Cre), TRPM7 modulates platelet function via regulation of cellular Mg2+ homeostasis
and cytoskeletal myosin IIA activity. Members of a human pedigree with mutations in TRPM7
(p.C721G), causing disrupted channel activity, suffer from macrothrombocytopenia and arterial
fibrosis. The defect in platelet biogenesis is mainly caused by cytoskeletal alterations resulting in
impaired pro-platelet formation by TRPM7-deficient megakaryocytes, which is rescued by Mg2+
supplementation [79]. In contrast, homozygous kinase-dead TRPM7R/R mice show normal platelet
counts, size and morphology, thus suggesting that the lack of TRPM7 channel rather than its kinase
activity accounts for the macrothrombocytopenia in Trpm7fl/fl-Pf4Cre mice [79]. However, the kinase
controls platelet function in arterial thrombosis via regulation of Ca2+ responses, Syk and PLCγ2
activity. Bone marrow (BM) chimeras revealed that the kinase is not only relevant for platelet function,
as both, recipients of WT BM as well as WT recipient of Trpm7R/R BM, developed reduction in infarct
size and improvement of neurological and motoric functions in an in vivo transient middle cerebral
artery occlusion (tMCAO) model. Thus, TRPM7 kinase activity in neurons and glial cells may also be
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critical for the progression of ischemic brain infarction [11]. These findings highlight TRPM7 kinase as
a potential target for the treatment of thrombosis thus protecting from stroke or myocardial infarction.
3.3. TRPM7 Kinase Signalling Supports Graft versus Host Reactions
Graft versus host disease (GVHD) is the most common side effect of an allogeneic hematopoietic
stem cell transplantation (HCST). In this immune reaction the donor T cells recognize the patients
human leukocyte antigen (HLA) as foreign, causing an inflammatory cascade [97]. GVHD can
be divided into acute and chronic, depending on the time of diagnosis [98]. In acute GVHD the
pre-transplant radiation may cause tissue damage in the host, leading to the activation of antigen
presenting cells followed by activation of the donor T cells. This can lead to severe damage of liver,
skin, mucosa and the gastrointestinal tract [99]. All in all, GVHD causes 15–30% of death after HCST,
highlighting the importance of enhancing the understanding of this disease and finding improved
treatments. Recently, it was shown that TRPM7 kinase activity promotes gut colonization by T cells
in acute GVHD. During this process, naïve donor CD4+ T cells recognize alloantigens on antigen
presenting cells in target organs, including the intestine (Figure 4C).
The role of different TH subsets and signalling pathways in the pathogenesis of GVHD is
incompletely understood. To address whether defective intestinal colonization by CD4+ T cells
lacking TRPM7 kinase activity could affect acute GVHD, the bone marrow (BM) of BALB/c WT mice
was lethally irradiated and replaced by bone marrow (BM) cells from WT C57BL/6 mice together with
WT or TRPM7R/R splenocytes. As expected, injection of WT splenocytes resulted in massive intestinal
damage and most mice died within 35 days after transplantation. In contrast, injection of TRPM7R/R
splenocytes did not cause intestinal damage and resulted in a dramatically increased survival of these
mice within the first 60 days after transplantation [20]. These results unravel a fundamental role of
TRPM7 kinase in T cell function and suggest a therapeutic potential of kinase inhibitors in averting
acute GVHD.
4. Conclusions
The involvement of TRPM7 in the pathogenesis of deregulated immune responses highlights
the necessity for novel pharmacological tools. TRPM7 represents a new promising drug target for
the treatment of pro-inflammatory diseases and hypersensitivity. It is tempting to speculate that
pharmacological modulation of TRPM7 may reinstate immune system homeostasis. Particularly
appealing is the fact that TRPM7 kinase-deficiency in mice does not result in an obvious phenotype
and only moderately affects haemostasis. Thus, TRPM7 kinase inhibition should not cause major side
effects. Therefore, new TRPM7 kinase inhibitors and novel kinase substrates have to be identified.
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